The predictive value of the Oncotype DX test to identify patients who could omit CT was further validated by the prospective randomized clinical trial TAILORx (Trial Assessing Individualized Options for Treatment) on 10,273 enrolled patients with ER+, HER2-negative N0 early breast cancer. This evidence concerns the gene ERBB2 and breast cancer.